Cardiovascular effects of recombinant human erythropoietin in predialysis patients
- 1 April 1997
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 29 (4) , 541-548
- https://doi.org/10.1016/s0272-6386(97)90335-8
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Long-Term Erythropoietin in Rats with Reduced Renal MassNephron, 1996
- Activation of the Sympathetic Nervous System in Hemodialyzed Patients Treated with ErythropoietinNephron, 1995
- Effectiveness and Safety of Recombinant Human Erythropoietin in Predialysis PatientsNephron, 1992
- Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients.Hypertension, 1990
- Treatment of the Anemia of Chronic Renal Failure with Recombinant Human ErythropoietinAnnual Review of Medicine, 1990
- Vascular changes in hemodialysis patients in response to recombinant human erythropoietinKidney International, 1989
- Impact of left ventricular hypertrophy on survival in end-stage renal diseaseKidney International, 1989
- Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal diseaseThe American Journal of Cardiology, 1989
- Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window.Circulation, 1984
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978